Highlights Immunocore Holdings plc

Equities

IMCR

US45258D1054

Market Closed - Nasdaq Other stock markets 21:00:00 21/06/2024 BST			5-day change	1st Jan Change
35.93 ^USD	+2.31%		-6.58%	-47.41%

06-18	Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment	MT
06-18	Immunocore Holdings plc Announces Randomization of First Patient in the Global, Registrational Phase 3 Clinical Trial Testing Brenetafusp for the Treatment of First-Line Advanced or Metastatic Cutaneous Melanoma	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment	06-18	MT
Immunocore Holdings plc Announces Randomization of First Patient in the Global, Registrational Phase 3 Clinical Trial Testing Brenetafusp for the Treatment of First-Line Advanced or Metastatic Cutaneous Melanoma	06-18	CI
Immunocore Holdings plc Presents KIMMTRAK Clinical Data Demonstrating That Patients with Stable Disease and Confirms Tumor Reduction Have Similar Clinical Outcomes to Patients with Partial Response	06-01	CI
Immunocore Holdings plc Reports Updated Phase 1 Data of Brenetafusp (IMC-F106C), an ImmTAC Bispecific Targeting PRAME, in Immune Checkpoint Pre-treated Cutaneous Melanoma Patients at ASCO 2024	05-31	CI
Immunocore Holdings plc Converts Phase 2/3 TEBE-AM Clinical Trial into Registrational Phase 3 Trial Evaluating KIMMTRAK for Previously Treated Advanced Cutaneous Melanoma	05-29	CI
Immunocore Holdings' Shares Fall After Q1 Net Loss Widens	05-08	MT
Earnings Flash (IMCR) IMMUNOCORE HOLDINGS Reports Q1 Revenue $70.5M	05-08	MT
Immunocore Holdings plc Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Immunocore Holdings Files Mixed-Securities Shelf Registration	03-21	MT
Immunocore Holdings' Q4 Net Loss Narrows, Revenue Rises	02-28	MT
Earnings Flash (IMCR) IMMUNOCORE HOLDINGS LIMITED Reports Q4 Revenue $70.2M, vs. Street Est of $68.5M	02-28	MT
Immunocore Holdings plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-28	CI
Immunocore Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Immunocore Collaborates With Bristol Myers Squibb in Advanced Cutaneous Melanoma Trial	02-22	MT
Immunocore Holdings plc Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2023	01-29	CI
Immunocore Holdings plc Announces the Addition of Two New Pre-Clinical Candidates for Autoimmune Diseases to Its Pipeline	01-05	CI
Immunocore Holdings plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Immunocore's Q2 Net Loss Widens, Revenue Climbs	10/08/23	MT
Immunocore Holdings plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Immunocore Holdings plc Reports Earnings Results for the First Quarter Ended March 31, 2023	10/05/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Immunocore Holdings plc

Equities

IMCR

US45258D1054

Highlights

Filters